Proteinuria and VEGF-targeted therapies: An underestimated toxicity?

Journal of Nephrology

Volumn 26, Issue 5, 2013, Pages 807-810

  Izzedine, Hassane ^a   Soria, Jean Charles ^b   Escudier, Bernard ^b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Anti VEGF therapy; Proteinuria; Thrombotic microangiopathy

Indexed keywords

AFLIBERCEPT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PAZOPANIB; SUNITINIB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A;

ARTICLE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FOCAL GLOMERULOSCLEROSIS; GLOMERULOPATHY; HEMOLYTIC ANEMIA; HUMAN; HYPERTENSION; KIDNEY BIOPSY; KIDNEY FAILURE; MOLECULARLY TARGETED THERAPY; NEPHROSIS; NEPHROTIC SYNDROME; NEPHROTOXICITY; PLASMAPHERESIS; PROGNOSIS; PROTEINURIA; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRANSFUSION; ADULT; AGED; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DRUG EFFECTS; FEMALE; MALE; METABOLISM; MIDDLE AGED; MORTALITY; NEOPLASMS; PATHOLOGY; RISK FACTOR; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; TIME; VASCULARIZATION;

ADULT; AGED; ANGIOGENESIS INHIBITORS; DRUG SUBSTITUTION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PROGNOSIS; PROTEINURIA; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84884657534     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/jn.5000307     Document Type: Article

References (7)

1. Izzedine H, Massard C, Spano JP, Goldwasser F, Khayat D, Soria JC. VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management. Eur J Cancer. 2010; 46(2): 439-448.
2. Izzedine H, Rixe O, Billemont B, Baumelou A, Deray G. Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. Am J Kidney Dis. 2007; 50(2): 203-218.
3. Wu S, Kim C, Baer L, Zhu X. Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol. 2010; 21(8): 1381-1389.
4. Yeh J, Frieze D, Martins R, Carr L. Clinical utility of routine proteinuria evaluation in treatment decisions of patients receiving bevacizumab for metastatic solid tumors. Ann Pharmacother. 2010; 44(6): 1010-1015.
5. Han TM, Naicker S, Ramdial PK, Assounga AG. A crosssectional study of HIV-seropositive patients with varying degrees of proteinuria in South Africa. Kidney Int. 2006; 69(12): 2243-2250.
6. US Department of Health and Human Services. National Institutes of Health. National Institue Cancer. Available at: http://evs. nci. nih. gov/ftp1/CTCAE/About. html. Accessed June 2013.
7. Meyrier A. Transjugular renal biopsy: update on hepato-renal needlework. Nephrol Dial Transplant. 2005; 20(7): 1299-1302.